Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Results from CABOSUN, METEOR and JAVELIN trials in kidney cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.11.18
Views: 659

Dr Toni Choueri - Dana-Farber Cancer Institute, Boston, USA

Dr Choueri speaks with ecancer at ESMO 2018 in Munich about the latest in kidney cancer, with results from the CABOSUN trial comparing TKIs cabozantinib and sunitinb, the METEOR trial of cabozantinib and everolimus, and the JAVELIN 101 trial of sunitinib and avelumab axitinib.

He describes the significance of PD1 positivity in the JAVELIN 101 study, and what this might mean for future immunotherapy combinations.

Contrasting the results from JAVELIN and CABOSUN trials, which both offer a superior treatment to sunitinib, Dr Choueri weighs the different options available for patients.


ESMO 2018

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation